Authors
Latest:
Dr Chase on the FDA Approval of Dostarlimab Plus Chemotherapy in Endometrial CancerDana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.
Latest:
Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian CancerDana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.
Latest:
Dr. Rathkopf on AR-V7 Biomarker in Prostate CancerDana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.
Latest:
Mission Possible: Managing Specialty Pharmacy Costs and UtilizationTo get the right drug in the right amount at the right time to the patient in the most cost-effective manner
Latest:
Dana Jacoby on How a Group of Physicians Can Become a Successful Medical GroupDana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.
Latest:
Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR AgentsPanelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.
Latest:
Dana Monroe on Yervoy Side Effect Nurse Self-EducationDana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate
Latest:
Dr. James on Update of Ibrutinib for Chronic Lymphocytic LeukemiaDanelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.
Latest:
Discussion of RESORCE TrialPanelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.
Latest:
Dr. Barocas on Adjuvant Sunitinib in Renal Cell CarcinomaDaniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.
Latest:
Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate CancerDaniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.
Latest:
Dr. Osman on the 29th Miami Breast Cancer ConferenceDr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting
Latest:
Dr. Pollyea on Indications for Anti-CD33 Therapy in AMLDaniel Pollyea, MD, MS, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia.
Latest:
Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLCDaniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Catenacci on Navigating HER2 Testing in Gastric/GEJ CancerDaniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.
Latest:
Dr. Costin on Initial Considerations in Early-Stage Lung CancerDan Costin, MD, discusses initial considerations in early-stage lung cancer.
Latest:
Patient Education on Oral ChemotherapyDaniel DeRemer, PharmD, assistant director of Clinical Therapeutics and Incubator, discusses patient education on oral chemotherapy.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate CancerDaniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.
Latest:
Dr. Hayes on the Future of Biomarkers for Breast CancerDaniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.
Latest:
Dr. Coit on the Evolving Role of Surgery in Patients With MelanomaDaniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.
Latest:
Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast CancerGrowing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.
Latest:
Dr George on Other Potential Roles for Radioligand Therapy in Prostate CancerDaniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.
Latest:
Dr. Ahn on the Evolution of First-line Treatment Options in HCCDaniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.
